TQC2731 is named as an intervention in 3 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. The most-studied condition is Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784 · ClinicalTrials.gov ↗ · Asthma
|
Phase 3 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | China |
|
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
|
Phase 3 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | China |
|
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease
|
Phase 2 | Active, closed | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name TQC2731 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how TQC2731 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TQC2731 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TQC2731 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.